CMS Restricts Community Oncology Practices from Mailing Medications, Raising Concerns for Cancer Patients

The Centers for Medicare & Medicaid Services (CMS) has implemented restrictions that prevent community oncology practices from mailing medications directly to patients, raising concerns about the potential impact on cancer care delivery. According to David Eagle, MD, Chair of Legislative Affairs and Patient Advocacy, this policy creates disparities between community oncology practices and pharmacy benefit managers (PBMs), while also imposing additional challenges for vulnerable cancer patients who rely on timely access to their treatments.

Dr. Eagle highlighted that the ban disproportionately affects smaller oncology practices that serve local communities. Unlike PBMs, which are allowed to mail medications, these practices must now find alternative methods to deliver prescriptions, potentially delaying treatment for patients with critical needs. He noted that many cancer patients face mobility issues or live in areas without easy access to pharmacies, making the ability to receive medications by mail an essential service. The restriction could lead to increased logistical hurdles for both providers and patients, particularly those already navigating complex treatment regimens.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

Date: September 3, 2025

Related posts:

Matthew Lei Highlights Community, Collaboration, and Innovation at HOPA Annual Conference AbbVie Pledges Donations for Cancer Causes Based on Chicago Cubs Pitchers’ Strikeouts Supreme Court Reviews Case on Puberty Blockers and Hormone Therapy for Transgender Youth āshibio Secures Exclusive License from Mereo BioPharma to Develop Vantictumab for Rare Bone Disorder

Author

Mark Chiang